Taiwan has made encouraging progress in biopharmaceutical development, as two new drugs developed by local companies with government assistance have received international recognition recently, an official said yesterday.
PharmaEssentia Corp (藥華醫藥), a Taipei-based pharmaceutical company founded by a group of Taiwanese-American scientists in 2003, has received Investigational New Drug (IND) approval from US and Canadian authorities for its third-generation interferon drug candidate P1101 (PEG-P-IFN-alpha-2b), the Ministry of Economic Affairs (MOEA) official said.
CLINICAL TRIALS
The drug, which treats hepatitis B and C and is particularly long-acting compared to the two other pegylated-interferon drugs currently on the market, will begin phase 1 clinical trials in both Canada and Taiwan later this year.
It already received IND approval from Taiwan’s Department of Health in June.
Meanwhile, the MOEA official said GlycoNex Inc (台灣醣聯生技) has successfully developed a potential therapeutic drug for colorectal cancer, known as fully human monoclonal antibody GNX-8.
AGREEMENT
GlycoNex has recently signed an agreement with Japanese pharmaceutical company Otsuka Pharmaceutical for technology transfer, the official said.
Once the potential colorectal cancer treatment drug is successfully marketed, GlycoNex could rake in about US$500 million (NT$16.2 billion) in royalties annually.
According to GlycoNex chairman Tong Chang (張東玄), the new drug is expected to fully attack cancerous cells without hurting healthy cells.
Attracted by the drug’s promising global market potential, Otsuka has decided to complete follow-up clinical trials.
SUPPORT
As development of biotechnology and new pharmaceuticals entails high risks and requires a heavy capital infusion and a long period of time, the official said, the MOEA has supported many development projects through the government-funded Development Center for Biotechnology.
For instance, he said, the MOEA put up NT$57 million between 2003 and 2006 to subsidize the development of GlycoNex’s cancer treatment drug and has contributed NT$53 million since 2006 to help PharmaEssentia develop its hepatitis B/C drug.
In addition, the official said, the DCB has set up world-class facilities — including a GPCR (G-Protein Coupled Receptors) Drug Discovery Facility and the Center of Toxicology and Preclinical Sciences — to help local pharmaceutical companies research and develop new drugs.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
RSS